Marc Brickman, DO
Internal Medicine · Prescott, AZNPI 1437101789
Payments from drug & device makers
Across 160 payments — averaging $16.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$444
- AstraZeneca$272
- Lilly USA, LLC$200
- Pfizer$167
- Amgen$163
- GSK$154
- plus $1K from 30 others
What the payments were for
- Food & beverage$2,57599%
- Education$171%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 30 | $444 |
| AstraZeneca | 18 | $272 |
| Lilly USA, LLC | 10 | $200 |
| Pfizer | 13 | $167 |
| Amgen | 11 | $163 |
| GSK | 10 | $154 |
| Novo Nordisk | 8 | $148 |
| Johnson & Johnson(2 entities) | 7 | $98 |
| Astellas Pharma US Inc | 5 | $86 |
| Boehringer Ingelheim | 4 | $83 |
| Novartis | 4 | $76 |
| Exact Sciences | 3 | $72 |
| Dexcom, Inc. | 4 | $65 |
| Merck | 4 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Medicure Pharma Inc. | 1 | $46 |
| Antares Pharma, Inc. | 3 | $44 |
| Xeris Pharmaceuticals, Inc. | 2 | $44 |
| Insulet Corporation | 2 | $36 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Amarin Pharma, Inc. | 2 | $26 |
| Abbott | 1 | $21 |
| Cook Medical LLC | 1 | $18 |
| Stryker | 1 | $17 |
| Esperion Therapeutics, Inc. | 1 | $17 |
| AMAG Pharmaceuticals, Inc. | 1 | $17 |
| Biohaven Pharmaceuticals, Inc. | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| GE HealthCare | 1 | $15 |
| Daiichi Sankyo Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
| Halozyme Inc | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $13 |
| Boston Scientific | 1 | $12 |
| Endogastric Solutions, Inc | 1 | $12 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
How this compares
$2,592 in reported general payments places this provider in the 85th percentile of 2,212 internal medicine providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 62 | $66,461 |
| MounjaroTirzepatide | 54 | $58,157 |
| JardianceEmpagliflozin | 40 | $44,111 |
| OzempicSemaglutide | 20 | $29,507 |
| FarxigaDapagliflozin Propanediol | 24 | $25,694 |
| XareltoRivaroxaban | 20 | $22,641 |
| EntrestoSacubitril/Valsartan | 15 | $17,771 |
| JanuviaSitagliptin Phosphate | 16 | $16,532 |
| TradjentaLinagliptin | 13 | $12,576 |
| QuviviqDaridorexant Hcl | 18 | $9,649 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 11 | $8,660 |
| Levothyroxine Sodium | 245 | $3,235 |
| Rosuvastatin Calcium | 227 | $2,984 |
| SynthroidLevothyroxine Sodium | 52 | $2,916 |
| Droxidopa | 18 | $2,817 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Paxlovid | $167 | $67,82983 claims |
| Lilly USA, LLCMounjaro | $200 | $58,15754 claims |
| Boehringer IngelheimJardiance, Tradjenta | $83 | $56,68753 claims |
| Novo NordiskOzempic | $148 | $29,50720 claims |
| AstraZenecaFarxiga | $272 | $25,69424 claims |
| Johnson & JohnsonXarelto | $98 | $22,64120 claims |
| NovartisEntresto | $76 | $17,77115 claims |
| MerckJanuvia | $57 | $16,53216 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $31 | $9,64918 claims |
| GSKTrelegy Ellipta | $154 | $8,66011 claims |
| AbbVieSynthroid | $444 | $2,91652 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,212 internal medicine providers in Arizona.
Other internal medicine in Prescott
- Yessica SachdevaMesa$13.7M
- Louise TaberPhoenix$8.5M
- Janelle WeyerChandler$5.5M
- Robert MutterperlTucson$5.3M
- Jalal AbbasSun City West$4.8M
- Nebojsa SkrepnikTucson$4.7M
- Philip MathewTempe$4.1M
- Justin MoserScottsdale$3.9M
- Franz RischardTucson$3.7M
- Randall SeveranceChandler$3.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.